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© Qalys Health Economics 2008Background
 WHO recommendation to replace d4T
 Scaling-up
 Problem: How much will it cost?
 Tool: Health economic model
© Qalys Health Economics 2008Objectives
Develop a model to:
 Support decision making
 Demonstrate budget impacts
 Compare timing of introdcution
 Forecast ART budget 2008 - 2014
© Qalys Health Economics 2008Tenofovir vs. Stavudine
Tenofovir (TDF)
 WHO recommendation
 Better toxicity profile
 Once a day dosing
 TDF $128 PPY
Stavudine (d4T)
 d4T $19 PPY
 Significant toxicitìes
 Fixed dose combination:
d4T / 3TC / NVP 
30mg / 150mg / 200mg
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3TC
d4T NVP
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© Qalys Health Economics 2008ART survival and 2nd-line switch rate
 Global Cohort MSF
57.000 ART patients
 Extrapolated after 48 
months
 ART survival 9.7 years
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Epworth, Harare township
 Population 400.000
 20% infected with HIV
MSF program
 6.000 HIV+ patients 
 1.400 on ART
 First ARTs April 2007
 150 new patients / month
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 Patient volume
Nr of patients, speed of scaling-up
 Medical data
ART regimens, ART survival, rate of switch to 2nd-line, CD4 baselines
 Financial information
Forecasted ART prices, actual expenditures, annual budget
 Sensitivity analyses
© Qalys Health Economics 2008Base case: All patients on d4T/3TC/NVP 
$1.8M
© Qalys Health Economics 2008All patients on TDF/3TC/EFV 2008
$8.8M
$1.8M
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© Qalys Health Economics 2008All patients on TDF/3TC/NVP 2008
$6.6M
$1.8M
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Cipla 19 USD d4T
Aubindo
Hetero









Hetero 101 USD 146 USD EFAVIRENZ
Cipla 27 USD 35 USD LAMIVUDINE
Hetero 88 USD 128 USD TENOFOVIR
Manufacturer Price in 2014 Current price Drug
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 Potential cost savings:
from better toxicity profile of TDF
 ART price development
 Inadequate TDF survival data
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Forecasting human resource needs
 High cost of TDF and EFV
 Major barrier in resource poor settings
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